Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM; AN1792(QS-21)-201 Study Team.

Neurology. 2005 May 10;64(9):1553-62.

PMID:
15883316
2.

Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis.

Pride M, Seubert P, Grundman M, Hagen M, Eldridge J, Black RS.

Neurodegener Dis. 2008;5(3-4):194-6. doi: 10.1159/000113700. Epub 2008 Mar 6. Review.

PMID:
18322388
3.

Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy.

Ghochikyan A.

CNS Neurol Disord Drug Targets. 2009 Apr;8(2):128-43. Review.

4.

Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.

Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Logroscino G, Santamato A, Greco A, Seripa D, Pilotto A.

Immunotherapy. 2012 Feb;4(2):213-38. doi: 10.2217/imt.11.170. Review.

PMID:
22339463
5.

Alternative Abeta immunotherapy approaches for Alzheimer's disease.

Town T.

CNS Neurol Disord Drug Targets. 2009 Apr;8(2):114-27. Review.

6.
7.

Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention.

Cribbs DH.

CNS Neurol Disord Drug Targets. 2010 Apr;9(2):207-16. Review.

8.

Amyloid-beta immunotherapy for Alzheimer's disease.

Fu HJ, Liu B, Frost JL, Lemere CA.

CNS Neurol Disord Drug Targets. 2010 Apr;9(2):197-206. Review.

9.

Can Alzheimer disease be prevented by amyloid-beta immunotherapy?

Lemere CA, Masliah E.

Nat Rev Neurol. 2010 Feb;6(2):108-19. doi: 10.1038/nrneurol.2009.219. Review. Erratum in: Nat Rev Neurol. 2010 Apr;6(4):183. Nat Rev Neurol. 2010 Jun;6(6):296.

10.

Galantamine for Alzheimer's disease and mild cognitive impairment.

Loy C, Schneider L.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD001747. Review.

PMID:
16437436
11.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2001;(4):CD001747. Review. Update in: Cochrane Database Syst Rev. 2002;(3):CD001747.

PMID:
11687119
12.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2002;(3):CD001747. Review. Update in: Cochrane Database Syst Rev. 2004;(4):CD001747.

PMID:
12137632
13.

Anti-β-amyloid immunotherapy for Alzheimer's disease: focus on bapineuzumab.

Panza F, Frisardi V, Imbimbo BP, Seripa D, Paris F, Santamato A, D'Onofrio G, Logroscino G, Pilotto A, Solfrizzi V.

Curr Alzheimer Res. 2011 Dec;8(8):808-17. Review.

PMID:
21592055
14.

Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials.

Menéndez-González M, Pérez-Piñera P, Martínez-Rivera M, Muñiz AL, Vega JA.

Curr Pharm Des. 2011;17(5):508-20. Review.

PMID:
21375481
15.
16.

Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease.

Blennow K, Hampel H, Zetterberg H.

Neuropsychopharmacology. 2014 Jan;39(1):189-201. doi: 10.1038/npp.2013.154. Epub 2013 Jun 25. Review.

17.

Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease.

Panza F, Frisardi V, Imbimbo BP, D'Onofrio G, Pietrarossa G, Seripa D, Pilotto A, Solfrizzi V.

Immunotherapy. 2010 Nov;2(6):767-82. doi: 10.2217/imt.10.80. Review.

PMID:
21091109
18.
19.

New developments of clinical trial in immunotherapy for Alzheimer's disease.

Yang C, Xiao S.

Curr Pharm Biotechnol. 2015;16(6):484-91. Review.

PMID:
25860060
20.

Immunotherapy in a natural model of Abeta pathogenesis: the aging beagle.

Vasilevko V, Head E.

CNS Neurol Disord Drug Targets. 2009 Apr;8(2):98-113. Review.

PMID:
19355931
Items per page

Supplemental Content

Write to the Help Desk